Scott K. Dessain
Scott K. Dessain | |
---|---|
Alma mater | Yale University (MD, PhD) Brown University (AB) |
Scientific career | |
Fields | Oncology, biochemistry, immunology, biotechnology |
Institutions | Lankenau Institute for Medical Research Thomas Jefferson University Whitehead Institute for Biomedical Research |
Scott K. Dessain is an American oncologist, research scientist, who is a professor at Lankenau Institute for Medical Research and an attending medical oncologist at Lankenau Medical Center, both in Wynnewood, Pennsylvania.[1] He also is co-founder and chief technology officer of Immunome, Inc., a biotechnology company in Philadelphia specializing in development of native human cancer antibodies targeted against cancer antigens. Dessain developed a technology that caused cells to glow, which had been licensed for use by others.
Education and career
[edit]Dessain earned his bachelor's degree from Brown University and his MD and PhD from Yale University.[1] He completed a residency in internal medicine at Brigham and Women’s Hospital in Boston, followed by a fellowship in medical oncology at the Dana Farber/Partners CancerCare program, also in Boston.[2]
In addition to his academic career, Dessain has worked as a biotechnology entrepreneur since 2006, when he co-founded Immunome. He served as chief scientific officer of Immunome until 2016, when he became chief technology officer.[3]
On 13 November 2017, Dessain named The Joseph and Ray Gordon Chair in Clinical Oncology and Research by the Lankenau Medical Center Foundation.[4]
Dessain was responsible for developing a technology that made cells glow, which was licensed to OCMS Bio.[5] He also contributed to various studies, including a Nature Communications study about salmonella typhimurium biofilm disruption and an MDPI study on human IgA monoclonal antibodies.[6][7] He has also worked in dilution cloning and with the antibody immunoglobulin A, among others.
Books
[edit]- Dessain SK, editor (2008). Human Antibody Therapeutics for Viral Diseases. Berlin: Springer. (Current Topics in Microbiology and Immunology; vol. 317). ISBN 3540721444.
- Dessain S, Fishman S (2016). Preserving the Promise: Improving the Culture of Biotech Investment. 1st ed. Cambridge (MA): Academic Press. ISBN 0128092165.[8]
References
[edit]- ^ a b "Scott Dessain, MD, PhD". Lankenau Institute for Medical Research. Retrieved 10 October 2018.
- ^ "SKCC Staff Directory Page - Scott K. Dessain". Thomas Jefferson University. Retrieved 8 September 2017.
- ^ George, John. "Local biotech industry veterans: Marketplace setup 'dysfunctional' for investment". The Business Journals. Retrieved 8 September 2017.
- ^ "News – Lankenau Institute for Medical Research's Scott Dessain named t | Main Line Health | Philadelphia, Pennsylvania". Main Line Health. Retrieved 19 November 2017.
- ^ George, John (2020-01-30). "Guiding light: Main Line startup taps Lankenau Institute's glow tech to make antibodies". Biz Journals. Retrieved 2020-04-14.
- ^ Tursi, Sarah A.; Puligedda, Rama Devudu; Szabo, Paul; Nicastro, Lauren K.; Miller, Amanda L.; Qiu, Connie; Gallucci, Stefania; Relkin, Norman R.; Buttaro, Bettina A.; Dessain, Scott K.; Tükel, Çagla (2020-02-21). "Salmonella Typhimurium biofilm disruption by a human antibody that binds a pan-amyloid epitope on curli". Nature Communications. 11 (1): 1007. Bibcode:2020NatCo..11.1007T. doi:10.1038/s41467-020-14685-3. PMC 7035420. PMID 32081907.
- ^ Puligedda, Rama Devudu; Vigdorovich, Vladimir; Kouiavskaia, Diana; Kattala, Chandana Devi; Zhao, Jiang-Yang; Al-Saleem, Fetweh H.; Chumakov, Konstantin; Sather, D. Noah; Dessain, Scott K. (2020-01-02). "Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression". Antibodies. 9 (1): 5. doi:10.3390/antib9010005. PMC 7148538. PMID 32121092.
- ^ Luong, Thai. "Why the Drug You'll Need to Save Your Life in 15 Years Won't be There |". Elsevier. Retrieved 8 September 2017.
External links
[edit]- Scott K. Dessain publications indexed by Google Scholar